Drug Res (Stuttg) 2020; 70(04): 165-169
DOI: 10.1055/a-1110-7034
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity

Elham Beiranvand
1  Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
,
Seyed Nasser Ostad
2  Toxicology and Poisoning Research Centre, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
,
Esmat Mirabzadeh Ardakani
1  Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
,
Fatemeh Torkashvand
1  Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
,
Soroush Sardari
1  Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
,
Behrouz Vaziri
1  Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
› Author Affiliations
Further Information

Publication History

received 07 January 2020
revised 28 January 2020

accepted 30 January 2020

Publication Date:
19 February 2020 (online)

Abstract

Cardiac dysfunction is a major side effect of trastuzumab therapy for patients with HER2-positive breast cancer. Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy. In the present study, the preservability effects of carvedilol on trastuzumab-induced left ventricular (LV) dysfunction and the reversibility of trastuzumab-induced cardiotoxicity were evaluated in Wistar rats by echocardiography method. We showed that trastuzumab treatment of rats could induce the LV dysfunction through increasing the LV internal systolic diameter (LVIDs), increasing the end-systolic volume (ESV), decreasing the ejection fraction (EF), and decreasing the fractional shortening (FS). These parameters were not reversed after 14 days of stopping trastuzumab administration. Interestingly, carvedilol improved LVIDs, ESV, EF, and FS. Collectively, the results of this study have verified clinical observations which simultaneously administration of carvedilol may be considered as a possible therapeutic strategy to prevent trastuzumab-mediated LV dysfunction.